拜玛林制药

Biomarin's 15-min chart sees MACD Death Cross and KDJ Death Cross signals.

Biomarin's 15-Min Chart Shows MACD Death Cross, KDJ Death Cross

Biomarin's 15min chart triggered MACD Death Cross, Bearish Marubozu, Warning Signs

Biomarin

Amicus Therapeutics

BioMarin Pharmaceuticals' Acquisition of Amicus Therapeutics: A Strategic Play in Rare Diseases

BioMarin Pharmaceutical: Should You Buy Before Q4 Earnings?

Catalyst<ul> <li>Fund flows show positive net inflow across all order sizes including extra-large buckets indicating strong demand.</li></ul>Risk<ul> <li>Technical indicators show bearish signals are dominant with four negative patterns and no bullish ones in recent period.</li> <li>The technical side is weak with recent signals like Long Upper Shadow and RSI Overbought suggesting risk of decline.</li></ul>

Key Factors

BioMarin Pharmaceutical is proceeding with a $4.8 billion all-cash acquisition of Amicus Therapeutics at $14.50 per share, pending resolution of U.S. patent litigation with Aurobindo and Lupin.

Recent Updates

BMRN News